Search results

I answered “It depends”. Does payments include reimbursing transportation costs? I think it is important to make studies accessible to everybody. Other than that, I don’t think payments are overly productive. We all profit from well-conducted research and extra dollars spent there are probably...

LB0003 Dazodalibep (VIB4920/HZN4920) in Sjögren’s Subjects with an Unacceptable Symptom Burden: Safety and Efficacy from a Phase 2, Randomized, Double-Blind Study Abstract Background Sjögren’s is a systemic autoimmune disease associated with marked morbidity and poor health-related quality of...

Nucleocapsid protein accumulates in renal tubular epithelium of a post-COVID-19 patient ABSTRACT In this study, we investigated whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral proteins and virus particles can be detected (i) in post-mortem kidney of fatal coronavirus...

Herpes simplex virus 2 serology is associated with thinner whole-brain cortex in community-dwelling older adults Highlights We explore the association between infectious disease serologies and neuroimaging signatures Herpes simplex virus 2 was robustly associated with reduced whole-brain...

This has to be the weirdest announcement of funding ever. They are talking about announcing funding, but not actually talking about how half of the useful funding was already spent a long time ago in 2021, 2022 and 2023. Politics and political headlines I guess... A good summary on the funding...

In particular with respect to current Long-Covid research, it would be interesting what the results of such a study for a prolonged treatment would yield.

SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy Abstract Background: Data are conflicting regarding an association between treatment of acute COVID-19 with nirmatrelvir–ritonavir (N-R) and virologic rebound (VR). Objective: To compare the frequency of VR in patients with and...

A new Piece written in Time titled "Long COVID Reseearch Needs a Radical New Approach"- “How to End the Futile Blame Game Over Failed Long COVID Research” has been published. The article uses ME/CFS as example why there should be less biomedical research and instead a focus on things such as...

I think the point of the study is to validate the SIMOA assay, which has been, and is currently being tested in multiple studies as well as establishing best use practices for it, rather than doing anything else.

Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathology Abstract Aging is a major risk factor for neurodegenerative diseases, and coronavirus disease 2019 (COVID-19) is linked to severe neurological manifestations. Senescent cells contribute to brain aging, but...

The effect of donepezil hydrochloride on post-COVID memory impairment: A randomized controlled trial Abstract Background: Post-Coronavirus Disease (COVID-19) condition, known as "post-COVID syndrome," is associated with a range of complications persisting even after recovery. Among these...

Persistent cognitive slowing in post-COVID patients: longitudinal study over 6 months Abstract Background Fatigue is a frequent and one of the most debilitating symptoms in post-COVID syndrome (PCS). Recently, we proposed that fatigue is caused by hypoactivity of the brain’s arousal network...

This is the full thread https://threadreaderapp.com/thread/1722994818626781459.html. I have to agree with @Trish or at least I don't understand the reasoning why patients often communicate about trial results in placebo-controlled trials. What exactly is the point if the chances are far larger...

Almost half of the neuro-PCC were on antidepressants within the past 12 months. I can't tell whether that is due to a history of psychiatric symptoms (they include patients with worsened neuropsychiatric symptoms rather than just new neuropsychiatric symptoms) or because doctors love to describe...

Self-Reported Neuropsychiatric Post–COVID-19 Condition and CSF Markers of Neuroinflammation Introduction Long COVID, also known as post–COVID-19 condition (PCC), refers to a range of symptoms that may persist for weeks to months after acute COVID-19. A subset of people with PCC report...

That’s encouraging. Their ATG13 work has been discussed here. The trial size is big (n=100) or it’s at least relatively big for the fact that it isn’t placebo controlled and that there has hardly been any mTOR and ATG-13 research in ME/CFS. Regarding @V.R.T. 's question on why there isn’t a...

I thought I'd quote these posts by @Kalliope and @ahimsa as they are in line with the above publication and add some more context.

With respect to patients having to have an infectious onset as well there being a time-limit for illness duration, I'm going to break a lance for the researchers conducting the study. I can see why one could do this. I haven't followed ME/CFS research half as long as most other people on this...

Well done @Grigor! I tried to scrutinize it to my very limited abilities, but there isn't anything I can criticise. I do believe the sentence "As a result, the term 'Exercise is Medicine' may not be directly applicable post-COVID condition patients exhibiting PEM. (1,3)" is missing a "to"...

@Manuel is Manuel Ruiz Pablos.